secwatch.observer — SEC 8-K summary
======================================

Issuer:     Nexalin Technology, Inc. (NXL)
CIK:        0001527352
Form:       8-K
Filed at:   2026-04-22T23:59:59+00:00
Accession:  0001829126-26-003765
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 1.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Nexalin advances pivotal HALO Clarity insomnia trial toward Q2 2026 enrollment with 160-patient study
--------------------------------------------------------------------------------

- Entered contract with Lindus Health for pivotal study; direct fees ~$944,820 plus pass-through expenses.
- 160-patient, triple-blinded, sham-controlled trial targeting moderate-to-severe insomnia.
- Enrollment expected to begin Q2 2026; study supports planned De Novo FDA submission.
- Published peer-reviewed data showed statistically significant improvements vs sham treatment.
- Global sleep tech market estimated at $29.3B in 2025, projected to reach $153.7B by 2035.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1527352/000182912626003765/0001829126-26-003765-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1527352/000182912626003765/nexalintec_8k.htm
  HTML page:      https://secwatch.observer/filing/0001829126-26-003765

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer